<DOC>
	<DOCNO>NCT03103282</DOCNO>
	<brief_summary>The objective post-market clinical follow-up study collect medical information patient implant PuraStat® , accord participate institution 's procedure standard care .</brief_summary>
	<brief_title>Post-market Clinical Study Confirm Safety Performance PuraStat® Absorbable Haemostatic Material Management Bleeding Vascular Surgery .</brief_title>
	<detailed_description />
	<mesh_term>Hemostatics</mesh_term>
	<criteria>Main Inclusion criterion : 1 . Male female patient ≥18 year old 2 . Subject undergoing elective carotid endarterectomy either patch reconstruction eversion technique 3 . Subject able give voluntary , write informed consent participate clinical study consent obtain 4 . Subject , , opinion Clinical Investigator , able understand clinical study , cooperate study procedure willing return require posttreatment followup Main exclusion criterion : 1 . Presence sequelae coagulation disorder 2 . Known allergy hypersensitivity component PuraStat® 3 . Concurrent participation another clinical trial medical device medicinal product 4 . Pregnant interested become pregnant duration study , breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>